Phase I/II trial of capecitabine (Cap) and oxaliplatin (Ox) in combination with bevacizumab (Bev) and imatinib (Ima) in patients with metastatic colorectal cancer (CRC): AIO KRK 0205.
G. von Wichert
No relevant relationships to disclose
T. Hoehler
No relevant relationships to disclose
C. C. Schimanski
No relevant relationships to disclose
M. H. Moehler
Consultant or Advisory Role - Roche; Sanofi
R. Hofheinz
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
S. Kanzler
No relevant relationships to disclose
A. Hinke
No relevant relationships to disclose
T. Seufferlein
No relevant relationships to disclose
J. Siebler
No relevant relationships to disclose
A. Hochhaus
No relevant relationships to disclose
D. Arnold
Consultant or Advisory Role - Roche
Honoraria - Roche
M. Hallek
No relevant relationships to disclose
U. T. Hacker
Honoraria - Novartis